The global CRISPR and Cas genes market grew at a compound annual growth rate (CAGR) of 20% between 2023 and 2033, and it has excellent growth prospects going forward.
By promoting more precise cellular and animal models of disease processes for medical use, genome editing is increasing the capacity to clarify the role of genetics in diagnostics. In particular, the method is employed to comprehend the evolution of microorganisms. Globally, governments have promoted investments in genome editing technologies, opening the door for the market expansion and sales of CRISPR and Cas genes.
Additionally, the use of CRISPR-Cas systems in diagnostics and the evaluation of evolutionary studies in prokaryotes has increased due to advancements in genome editing.
Download a Free Sample Copy of this Report - https://www.factmr.com/connectus/sample?flag=S&rep_id=4823
Since the Cas-9 approach represents a groundbreaking stride in the field of biomedical research, it is the most significant development in this field. Additionally, CRISPR/Cas 9 is being used to modify the genome of somatic cells in an effort to speed up the treatment of a number of genetic illnesses. Furthermore, it is anticipated that the COVID-19 pandemic will discover practical uses for this method to comprehend the unique coronavirus's mutation. These investigations have demonstrated that, in comparison to other methods like RT-PCR tests, CRISPR-based assays yield more accurate test findings. As the demand for genetically modified therapeutic alternatives for chronic diseases like cancer is expected to increase, a clinical trial was started in the United States in 2016 to use CRISPR for disease therapy.
Country-wise Insights
Why is the U.S. Leading the CRISPR and Cas Genes Market in North America?
Favorable healthcare legislation, a robust healthcare system, and significant biopharmaceutical R&D make the U.S. a key market driver.
What Fuels Demand Growth for CRISPR and Cas Genes in Germany?
Germany's market growth is supported by leading pharma and gene therapy firms, increasing research approvals, and strong biotech funding.
Category-wise Insights
Which Product is Expected to Dominate the Market?
Vector-based Cas systems hold 60% of the market, favored for producing stable cell lines and enabling high protein and RNA expression with reduced off-target effects.
Which Application Will Drive Revenue Growth?
DNA-free systems are gaining traction due to their versatility in CRISPR applications, including drug discovery, biomedical research, and clinical therapies.
Competitive Landscape
Leading companies are leveraging strategic initiatives like acquisitions, supply chain optimization, and the launch of advanced, eco-friendly products to strengthen their global presence. Collaborations with research institutes are driving R&D for treating diseases such as AIDS, cancer, and genetic disorders, while technological advancements and expanding applications intensify market competition.
- Thermo Fisher Scientific offers a diverse portfolio of CRISPR-Cas products, including CRISPR-Cas9 101, CRISPR Protein, gRNA, Cas9 Lentivirus, and Plasmids. It also collaborates with Synthego to distribute synthetic Guide RNA products.
- Casebia Therapeutics and Bayer AG joined forces in 2021 to research, develop, and commercialize innovative treatments for conditions like blindness, blood disorders, and congenital heart disease.
Key Segments of CRISPR and Cas Genes Industry Research
-
By Product :
- Vector-based Cas
- DNA-free Cas
-
By Application :
- Genome Engineering
- Disease Models
- Functional Genomes
- Knockdown/Activation
- Others
-
By End User :
- Biotechnology & Pharmaceutical Companies
- Academic & Government Research Institutes
- Contract Research Organizations
-
By Region :
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Contact:
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com
Comments
0 comment